Newsletter No1 / July 2024
1) The third on-site meeting was held on 27 May 2024 in Athens, Greece.
2) Poster presentations in Trials in Progress category: (i) ESMO Breast 2024 (15 – 17 May) presented by Antonios Valachis (ii) ASCO 2024 (30 May – 3 June) presented by Paris Kosmidis and Thanos Kosmidis
3) A paper based on IMPORTANT project deliverable was recently published: Karihtalaa P, Schiza A, Fountzilas E, Geisler J, Meattini I, Risi E, Biganzoli L, and Valachis A. Clinical trials in older patients with cancer– typical challenges, possible solutions, and a paradigm of study design in breast cancer. Acta Oncologica 2024; 63: 441–447
2) Poster presentations in Trials in Progress category: (i) ESMO Breast 2024 (15 – 17 May) presented by Antonios Valachis (ii) ASCO 2024 (30 May – 3 June) presented by Paris Kosmidis and Thanos Kosmidis
3) A paper based on IMPORTANT project deliverable was recently published: Karihtalaa P, Schiza A, Fountzilas E, Geisler J, Meattini I, Risi E, Biganzoli L, and Valachis A. Clinical trials in older patients with cancer– typical challenges, possible solutions, and a paradigm of study design in breast cancer. Acta Oncologica 2024; 63: 441–447
Newsletter No2 / August 2024
1) Three patients in Helsinki and one patient in Örebro have completed their first 3-month follow up
2) The amendment of the IMPORTANT trial protocol regarding some of the inclusion and exclusion criteria is ready for submission (see below in bold)
3) The inclusion criterion on RECIST assessment has been removed 4) The changes in the exclusion and inclusion criteria are to allow a broader patient inclusion and to serve the pragmatic scope of the trial. These changes have no impact on the informed consent form (ICF)
2) The amendment of the IMPORTANT trial protocol regarding some of the inclusion and exclusion criteria is ready for submission (see below in bold)
3) The inclusion criterion on RECIST assessment has been removed 4) The changes in the exclusion and inclusion criteria are to allow a broader patient inclusion and to serve the pragmatic scope of the trial. These changes have no impact on the informed consent form (ICF)
Newsletter No3 / September 2024
1) Five patients have completed their first 3-month follow up
2) IMPORTANT trial clinical lead, Antonios Valachis, will be attending the first meeting for Horizon Europe Cancer Mission ‘Diagnosis and Treatment’ cluster in Barcelona, Spain on 12 September 2024. IMPORTANT trial is one of the 12 funded projects under the cluster. Antonis will be chairing the round table discussion on `Addressing Inequalities´
2) IMPORTANT trial clinical lead, Antonios Valachis, will be attending the first meeting for Horizon Europe Cancer Mission ‘Diagnosis and Treatment’ cluster in Barcelona, Spain on 12 September 2024. IMPORTANT trial is one of the 12 funded projects under the cluster. Antonis will be chairing the round table discussion on `Addressing Inequalities´
Newsletter No4 / October 2024
1) Six patients have completed their first 3-month follow up
2) Clinical sites in Greece have received conditional approval from CTIS
3) The project will request for an extension of inclusion period from 30 months to 36 months, and one year extension
4) Abstract to San Antonio Breast Cancer Symposium (SABCS) 2024 has been accepted for trial in progress poster
5) Prof. Biganzoli presented IMPORTANT as part of her presentation on “MDT– case of an older adult with metastatic breast cancer´´ during ESMO 2024
6) The trial clinical lead, Assoc. Prof. Antonios Valachis, attended the 1st meeting for Horizon Europe Cancer Mission ‘Diagnosis and Treatment’ cluster in Barcelona, Spain on 12 September 2024
7) The project participated at the EU Researcher’s Night event in Nicosia, Cyprus on 27 September 2024, led by Dr Vasiliki Danilatou and Assoc. Prof. Christiana Markou from Eunomia Ltd
2) Clinical sites in Greece have received conditional approval from CTIS
3) The project will request for an extension of inclusion period from 30 months to 36 months, and one year extension
4) Abstract to San Antonio Breast Cancer Symposium (SABCS) 2024 has been accepted for trial in progress poster
5) Prof. Biganzoli presented IMPORTANT as part of her presentation on “MDT– case of an older adult with metastatic breast cancer´´ during ESMO 2024
6) The trial clinical lead, Assoc. Prof. Antonios Valachis, attended the 1st meeting for Horizon Europe Cancer Mission ‘Diagnosis and Treatment’ cluster in Barcelona, Spain on 12 September 2024
7) The project participated at the EU Researcher’s Night event in Nicosia, Cyprus on 27 September 2024, led by Dr Vasiliki Danilatou and Assoc. Prof. Christiana Markou from Eunomia Ltd
